CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer

S Sengupta; R Rojas; A Mahadevan; E Kasper; S Jeyapalan

doi:10.1093/omcr/omv010

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2-neu-positive breast cancer

Oxf Med Case Reports. 2015 Apr 10;2015(4):254-7. doi: 10.1093/omcr/omv010. eCollection 2015 Apr.

Authors

S Sengupta¹, R Rojas², A Mahadevan³, E Kasper⁴, S Jeyapalan⁵

Affiliations

¹ Department of Neurology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
² Department of Neuroradiology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
³ Department of Radiation Oncology , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
⁴ Department of Neurosurgery , Harvard Medical School, Beth Israel Deaconess Medical Center , Boston, MA , USA.
⁵ Department of Neurology, Tuft Medical School, Tufts Medical Center, Boston, MA.

Abstract

Nervous system relapse of patients with advanced HER2-neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which can both cross the blood-brain barrier, as combination therapy to treat HER2-neu-positive breast cancer with brain metastases.

Publication types

Case Reports